Drug Approval | December 27, 2023
Eugia Pharma Specialities receives USFDA final approval for Posaconazole Injection
The product is expected to be launched in December 2023
The product is expected to be launched in December 2023
US FDA approval based on NEURO-TTRansform Phase III results
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
The plant is yet to start commercial operations
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
The brands Aarne in Germany and Nalcrom in Canada and the Netherlands are being acquired
Development services for gene and cell therapies is planned to begin first in 2025
KBR will provide outreach, education and data analytics to support critical neuroscience research for the prevention and treatment of military members with CTE
Subscribe To Our Newsletter & Stay Updated
